Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4181992 | L'Encéphale | 2013 | 7 Pages |
Abstract
From a public health point of view, such findings indicate that the metabolic risks associated with SGA use in real-life conditions are widely underestimated. Regarding the temporal trends of antipsychotic prescription, with the dramatic rise of SGA use observed in most countries, it is a public health priority to improve metabolic monitoring in SGA users, irrespective of the underlying diagnosis. Since it is more complex to modify pre-existing inadequate practices than to initiate correct ones in new prescribers, great attention should be paid to the need for delivering strong messages regarding the metabolic risks associated with SGA prescription during the initial training of physicians.
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
H. Verdoux, Y. Gaudron, G.-R. Auleley, J. Deligne, C. Blum-Boisgard, A. Thiébaut, M. Tournier,